SIB 1553A

Drug Profile

SIB 1553A

Latest Information Update: 25 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Neuroprotectants; Nootropics
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 15 Oct 2003 A preclinical study has been added to the Alzheimer's disease and Cognition disorders pharmacodynamics section
  • 04 Aug 2003 Preclinical studies have been added to the adverse events and Alzheimer's disease and Cognition disorders pharmacodynamics sections
  • 16 Dec 1999 SIBIA Neurosciences has been acquired by, and integrated into, Merck & Co.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top